0001209191-18-057268.txt : 20181105 0001209191-18-057268.hdr.sgml : 20181105 20181105180055 ACCESSION NUMBER: 0001209191-18-057268 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181101 FILED AS OF DATE: 20181105 DATE AS OF CHANGE: 20181105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thomsen Jillian B. CENTRAL INDEX KEY: 0001433457 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 181160992 MAIL ADDRESS: STREET 1: C/O NEKTAR THERAPEUTICS STREET 2: 201 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-01 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001433457 Thomsen Jillian B. C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 0 1 0 0 SVP & Chief Accounting Officer Common Stock 2018-11-01 4 A 0 90000 0.00 A 161265 D This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest quarterly in substantially equal installments on November 15, 2020, February 15, 2021, May 15, 2021, and August 15, 2021, based on the reporting person's continued service with the Company. This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Mark A. Wilson, Attorney-in-Fact 2018-11-05